文献速递角膜与眼表疾病

美国 Medicare 人群中眼科羊膜移植的使用模式与费用

Utilization Patterns and Costs of Ocular Amniotic Membrane Grafts in the Medicare Population.
PubMed 文献 · Ophthalmology · 2025-08-26

该回顾性队列研究基于 2011 至 2020 年 Medicare Part B 全国代表性 20% 样本,分析无缝线眼表羊膜移植的使用量、费用与临床适应证。2020 年干眼占全部无缝线羊膜移植使用的 44%,较 2011 年的 7% 上升;作者认为报销模式推高了费用,建议要求制造商报告准确销售价格。

要点

  • 2020 年干眼占无缝线羊膜移植使用的 44%,2011 年为 7%。
  • 1% 的提供者提交了全部羊膜移植索赔的 28%。

核心结论

  • 作者认为皮肤替代物的报销模式推高了 Medicare 费用,即使临床指征有限也鼓励使用,这一担忧可能同样适用于眼科。
  • 作者建议政策制定者可要求羊膜移植制造商报告准确销售价格,从而在不限制适当临床指征覆盖的情况下降低成本。

研究设计与样本

  • 回顾性队列研究,使用 2011 至 2020 年 Medicare Part B 全国代表性 20% 样本,纳入接受无缝线羊膜移植的按服务收费患者及提交相关账单的眼科提供者。
  • 采用纵向患者层面与提供者层面数据,主要结局使用回归模型,时间至事件分析采用 Cox 比例风险生存模型,二分类结局采用逻辑回归模型。

主要发现

  • 2020 年干眼占全部无缝线羊膜移植使用的 44%,较 2011 年的 7% 上升。
  • 全部羊膜移植索赔中 28% 由 1% 的提供者提交。
  • 患者由验光师接诊时更可能接受羊膜移植(HR 1.16;P < 0.001)。
  • 在使用羊膜移植的提供者中,干眼患者每年给 Medicare 造成的费用大幅增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent investigations from the Office of the Inspector General and The New York Times have raised concerns about the costs to Medicare of skin substitutes, documenting pervasive fraudulent billing practices outside of ophthalmology. These investigations have not covered the use of tissue in eye care, despite similar reimbursement incentives for the use of sutureless ocular amniotic membrane grafts (AMGs). We examine the volume, cost, and clinical indications associated with sutureless AMGs in eye care. DESIGN: Retrospective cohort study of fee-for-service Medicare patients who received sutureless AMGs and eye care providers who bill for sutureless AMGs. PARTICIPANTS: Nationally representative 20% sample of Medicare Part B claims for sutureless AMGs between 2011 and 2020. METHODS: We use longitudinal patient-level and provider-level data to specify regression models for our primary outcomes. We estimate Cox proportional hazards survival models for time-to-event analyses and logistic regression models for binary outcomes. MAIN OUTCOME MEASURES: Clinical indications for AMG use, time from patients' first encounter with a provider to their first AMG, use of AMGs for dry eye, and costs to Medicare. RESULTS: Dry eye accounted for 44% of all sutureless AMG use in 2020, increased from 7% in 2011. Charges for ocular sutureless AMGs increased from $3.5 million in 2011 to $95.6 million in 2020; charges for AMGs used to treat dry eye increased from $250 000 to $41.4 million over this period. Some 28% of all claims for AMGS were submitted by 1% of providers. Patients are more likely to receive an AMG when seen by an optometrist (hazard ratio, 1.16; P < 0.001). The annual costs to Medicare for a patient with dry eye have increased dramatically among providers who use AMGs. CONCLUSIONS: The costs to Medicare for skin substitutes are inflated by reimbursement models that encourage their use even when there is little clinical indication. These concerns may be applicable to eye care as well, where spending on amniotic membrane grafts has increased dramatically, particularly for indications where clinical benefit may be limited. By requiring AMG manufacturers to report accurate sales prices, policymakers could reduce costs without limiting coverage of AMGs for appropriate clinical indications. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Vail DG, Nudleman E, Abdeljaber L, et al. Utilization Patterns and Costs of Ocular Amniotic Membrane Grafts in the Medicare Population. Ophthalmology. 2025. PMID: 40876599. doi:10.1016/j.ophtha.2025.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。